Bulk Suggestion
Bulk ID:
braviboron/05.13.25-04:03AM
Accepted at: May, 13, 2025
4:26 a.m.
Author:
braviboron
Co-authors:
Stapedius
Related Deck:
1675118865074
Accepted
Rationale for new note
CAP in children > 2 months
Text
What is the management of high severity community acquired pneumonia in children 2 months or older, suspected to be caused by Burkholderia pseudomallei?
{{c1::Meropenem IV}}
{{c1::Meropenem IV}}
Text
What is the management of <u>high severity</u> <b>community acquired pneumonia</b> in children 2 months or older, suspected to be caused by <i>Burkholderia pseudomallei</i>?<br><br>{{c1::Meropenem IV}}
Extra
Extra
<img src="476cb25115a941665c353ee63b7d44a5.webp">
Personal Notes
Empty field
Personal Notes
Missed Questions
Empty field
Missed Questions
Oxford Handbook
Empty field
Oxford Handbook
First Aid
Empty field
First Aid
AMBOSS
Empty field
AMBOSS
eTG Complete
eTG Complete
<img alt="webp image" src="0e5ade519177d5bc83d5709ac79da52a.webp">
Talley & O'Connor
Empty field
Talley & O'Connor
Additional Resources
Empty field
Additional Resources
Source
eTG - Community-acquired pneumonia (CAP) in children 2 months or older https://app-tg-org.au.eu1.proxy.openathens.net/viewTopic?etgAccess=true&guidelinePage=Antibiotic&topicfile=community-acquired-pneumonia-adults Published/Amended March 2025, Accessed 13 May 2025
Source
eTG - Community-acquired pneumonia (CAP) in children 2 months or older <a href="https://app-tg-org.au.eu1.proxy.openathens.net/viewTopic?etgAccess=true&guidelinePage=Antibiotic&topicfile=community-acquired-pneumonia-adults">https://app-tg-org.au.eu1.proxy.openathens.net/viewTopic?etgAccess=true&guidelinePage=Antibiotic&topicfile=community-acquired-pneumonia-adults</a> Published/Amended March 2025, Accessed 13 May 2025
One by one
Empty field
One by one
Tags
#Malleus_CM::#eTG_Complete::Antibiotic::Pneumonia::Community-acquired_pneumonia_(CAP)_in_children_2_months_or_older
#Malleus_CM::#Pharmacology::06_Anti-infectives::01_Antibacterials::02_Carbapenems::Meropenem::03_Indications
#Malleus_CM::#Question_Banks::eMedici::0-999::9
#Malleus_CM::#Question_Banks::eMedici::1000-1999::1153
#Malleus_CM::#Question_Banks::eMedici::1000-1999::1428
#Malleus_CM::#Resources_by_Rotation::Emergency
#Malleus_CM::#Resources_by_Rotation::Intensive_Care
#Malleus_CM::#Resources_by_Rotation::Internal_Medicine::General_Medicine
#Malleus_CM::#Resources_by_Rotation::Internal_Medicine::Haematology_&_Oncology
#Malleus_CM::#Resources_by_Rotation::Internal_Medicine::Infectious_Diseases
#Malleus_CM::#Resources_by_Rotation::Internal_Medicine::Neurology
#Malleus_CM::#Resources_by_Rotation::Internal_Medicine::Respiratory_Medicine
#Malleus_CM::#Resources_by_Rotation::Paediatrics
#Malleus_CM::#Resources_by_Rotation::Pharmacology
#Malleus_CM::#Subjects::Emergency_Medicine::04_Sepsis_&_Infectious_Emergencies::03_Respiratory_Infections::*General::Pneumonia_Classification::Community_Acquired_Pneumonia
#Malleus_CM::#Subjects::Emergency_Medicine::04_Sepsis_&_Infectious_Emergencies::03_Respiratory_Infections::Pneumonia::10_Management
#Malleus_CM::#Subjects::Emergency_Medicine::07_Respiratory_Failure::01_Hypoxic_Respiratory_Failure::Pneumonia::10_Management
#Malleus_CM::#Subjects::Infectious_Diseases::01_Bacteria::06_Gram_Negative_Bacilli::Burkholderia::10_Management
#Malleus_CM::#Subjects::Respiratory_Medicine::02_Lung_Infections::*General::Pneumonia_Classification::Community_Acquired_Pneumonia
#Malleus_CM::#Subjects::Respiratory_Medicine::02_Lung_Infections::Pneumonia::10_Management
#Malleus_CM::#Yield::High